6NOVEMBER - 2021TECH OUTLOOKEditorialStacey Smith Editor-in-Chiefeditor@pharmatechoutlook.com"Change is the only constant." These pearls of wisdom from the ancient Greek philosopher Heraclitus still hold true today. And it is most certainly true for the pharmaceutical sector where change is critical for survival. The race for a cure across complex therapeutic areas and individual diseases is becoming highly competitive, placing enormous pressure squarely on the drug development disciplines.While this past decade has witnessed major innovation--particularly around technologies such as AI and machine learning--in the drug development space to combat these shortcomings, this is only just the beginning. As we move into a new decade, we can expect to see a continued evolution of these technological innovations, all with the goal of expediting drug development. For instance, AI is expected to handle vast amounts of data and be used in target identification, big data analytics, forecasting, patient matching, automating molecule design, and more. Many pharmaceutical organizations are thus embracing and adopting AI-based technologies, such as machine learning, investing heavily in the belief that AI will reduce costs, shorten timelines, and lead to new and better drugs.In this edition of Pharma Tech Outlook, we bring you the story of some of the best-of-breed drug discovery solution providers who can augment the existing technological capabilities of their clients and deliver the best outcomes. This edition also offers a combination of thought leadership from subject matter experts and exclusive insights from CIOs and CXOs. We hope this edition will provide you with the right assistance in choosing the best drug discovery solution partners, according to your requirements. Let us know your thoughts!AI in Drug Development: A Glimpse into the Future of Drug DiscoveryTECH OUTLOOKTECH OUTLOOKCopyright © 2021 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.NOVEMBER - 08 - 2021, Vol 07 - Issue 17 (ISSN 2644-2787) Published by ValleyMedia, Inc. To subscribe to Pharma Tech OutlookVisit www.pharmatechoutlook.com *Some of the Insights are based on the interviews with respective CIOs and CXOs to our editorial staffEditor-in-ChiefStacey SmithVisualizerJaxon JaseEditorial StaffAaron Pierce Ava GarciaJenna VegasCarolynn Walters Justin SmithPaul BarberSalesBrian Thomasbrian@pharmatechoutlook.comPhone: 510.556.2402sales@pharmatechoutlook.comeditor@pharmatechoutlook.commarketing@pharmatechoutlook.comEmail:David Parker
< Page 5 | Page 7 >